Genetically Engineering Immune Cells: The Future of CAR-T Cell Therapy

Image Citation: [1]

Writer: Augusto Castaner ’29

Editor: Yumiko Imai ’26

Imagine your body’s immune cells are like a security force, and cancer cells are intruders that infiltrate your neighborhood block (body) and break into your home (an organ) wearing convincing disguises. For decades, these invaders were fought back with blunt force—chemotherapy and radiation—that damaged not only your house, but also the entire neighborhood (surrounding cells and tissues) and security force. But what if we could reprogram our security forces to be incredibly effective detectives, capable of seeing through the cancer cells’ disguises and taking them out with precision? This is what chimeric antigen receptor (CAR) T cell therapy promises to deliver–a novel treatment option that genetically engineers a patient’s own immune cells to fight cancer [2]. The results have been overwhelmingly positive for treating blood cancers with six CAR-T therapies already approved, achieving remission rates as high as 90% in some cases [2]. However, this powerful therapy has historically struggled with combating solid tumors, which make up about 90% of all adult cancers. Now, new advances are uncovering the causes of this failure and providing possible solutions, thus making modern CAR-T therapy smarter, safer, and more powerful than ever.

CAR-T therapy involves extracting a patient’s T cells, a key type of immune cell, and equipping them with a synthetic “homing device” called a chimeric antigen receptor. This receptor allows the T cells to recognize and bind to a specific protein present on the surface of cancer cells. Once the modified T cells are infused back into the patient, they multiply and launch a targeted attack [2]. Despite these advances, CAR-T cells have mostly failed at treating solid tumors due to a combination of poor infiltration, a suppressive tumor environment and, as recently discovered, a cunning counter-attack by the tumor itself [4, 5].

A major breakthrough in understanding how solid tumors resist CAR-T treatment comes from the discovery of a “fratricide” mechanism. Researchers found that when CAR-T cells attack solid tumors, the tumors respond by releasing a cloud of tiny particles called small extracellular vesicles (sEVs), or exosomes [5]. These sEVs are loaded with tumor antigens—the “disguises” that the CAR-T cells are trained to recognize.

These tumor-derived sEVs deliver their antigen “cargo” directly to the CAR-T cells. Essentially, the therapeutic cells are tagged, causing them to be misidentified as cancer cells by their fellow CAR-T cells, which leads them to destroy each other [5]. This is known as sEV-provoked fratricide and significantly reduces the number of CAR-T cells that can infiltrate and attack the tumor. Interestingly, it should be noted that this mechanism is less effective in blood cancers where CAR-T cells are shielded from fratricide [5].

Now equipped with this new understanding, researchers are designing solutions to overcome these challenges. The strategies can be broadly grouped into three categories: enhancing safety, boosting capability, and preventing self-destruction.

Firstly, to make CAR T-cell therapy safer, researchers are investigating how to manage cytokine release syndrome (CRS). CRS occurs because the rapid destruction of cancer cells can trigger a “friendly fire” situation, which causes patients to experience high fevers, dangerously low blood pressure, and even organ dysfunction in some cases [2, 3]. In order to manage cytokine release syndrome, researchers are installing something akin to molecular remote controls. One approach engineers CAR-T cells to be activated only by a separate bispecific adapter molecule [3]. By adjusting the adapter’s dose, doctors can regulate CAR-T activity with precision, reversing the effects of CRS in hours while still effectively eradicating tumors [3]. Another strategy currently being studied creates a type of physical shield using “in situ PEGylation,” where a long polymer is attached to CAR-T cells after infusion is done on a patient, physically blocking the dangerous interactions that drive CRS and neurotoxicity [4].

Secondly, in an attempt to make CAR-T cells more potent, researchers are looking to cancer itself for inspiration. By analyzing mutations from cancerous T cells, they identified a gene fusion, CARD11-PIK3R3, which acts as a “power-up” [6]. This mutation, when engineered into therapeutic CAR-T cells, greatly enhances the cells’ ability to kill tumors, survive for longer, and be able to function properly in harsh environments. This makes them up to 100 times more potent in studies conducted on mice [6].

Lastly, to counter the newly discovered fratricide mechanism, researchers have developed a new type of “armored” CAR-T cells, inspired by the self-protection mechanism seen in some types of blood cancers that protect themselves with a protein called Serpin B9. New CAR-T cells engineered to co-express the protective protein Serpin B9 are highly resistant to the sEV attack that provokes fratricide [5]. In preclinical models, this has been shown to lead to better survival odds, increased tumor infiltration, and improved efficiency in combating solid tumors, especially when combined with other existing immunotherapies [5].

The future of CAR-T cell therapy lies in how these advances will be integrated. Imagine a patient receiving “powered-up” CAR-T cells, which are armored against fratricide and equipped with a safety switch at the molecular level. These innovations are shaping CAR-T therapy from a risky, hospital-bound treatment that is largely ineffective against solid tumors into a safer, more capable and patient-centered treatment option in cancer care.

Sources

[1] Memorial Sloan Kettering Cancer Center. Car T Cells: Timeline of Progress [Internet]. New

York: MSKCC; [cited 2025 Oct 14]. Available from:

https://www.mskcc.org/timeline/car-t-timeline-progress

[2] Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history

and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. 

https://doi.org/10.3389/fimmu.2023.1188049

[3] Lee YG, Chu H, Lu Y, Leamon CP, Srinivasarao M, Putt KS, et al. Regulation of CAR T

cell-mediated cytokine release syndrome-like toxicity using low molecular weight

adapters. Nat Commun. 2019 June 18;10(1):2681. 

https://doi.org/10.1038/s41467-019-10565-7

[4] Gong N, Han X, Xue L, El-Mayta R, Metzloff AE, Billingsley MM, et al. In situ PEGylation

of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nat Mater. 2023

Dec;22(12):1571–80. 

https://doi.org/10.1038/s41563-023-01646-6

[5] Zhong W, Qin Z, Yu Z, Yang J, Yan D, Engel NW, et al. Overcoming extracellular

vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. Nat

Cancer. 2025 Apr 15;6(7):1157–72. 

https://doi.org/10.1038/s43018-025-00949-8

[6] Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, et al. Naturally occurring T cell mutations

enhance engineered T cell therapies. Nature. 2024 Feb 15;626(7999):626–34. 

https://doi.org/10.1038/s41586-024-07018-7